Eledon Pharmaceuticals (ELDN) and Its Competitors Head to Head Review

Eledon Pharmaceuticals (NASDAQ: ELDN) is one of 777 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Eledon Pharmaceuticals to related companies based on the strength of its analyst recommendations, valuation, earnings, profitability, institutional ownership, dividends and risk.

Earnings & Valuation

This table compares Eledon Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Eledon Pharmaceuticals	N/A	-$16.01 million	-0.77
Eledon Pharmaceuticals Competitors	$1.89 billion	$219.07 million	-5.16

Eledon Pharmaceuticals’ competitors have higher revenue and earnings than Eledon Pharmaceuticals. Eledon Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Eledon Pharmaceuticals has a beta of 1.92, indicating that its stock price is 92% more volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals’ competitors have a beta of 0.40, indicating that their average stock price is 60% less volatile than the S&P 500.

Institutional & Insider Ownership

44.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 2.2% of Eledon Pharmaceuticals shares are held by company insiders. Comparatively, 15.4% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Eledon Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Eledon Pharmaceuticals	N/A	-133.49%	-30.52%
Eledon Pharmaceuticals Competitors	-3,540.56%	-189.52%	-30.06%

Analyst Recommendations

This is a summary of current ratings and price targets for Eledon Pharmaceuticals and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eledon Pharmaceuticals	0	0	1	0	3.00
Eledon Pharmaceuticals Competitors	4276	16613	36699	747	2.58

Eledon Pharmaceuticals currently has a consensus price target of $34.00, indicating a potential upside of 105.56%. As a group, “Pharmaceutical preparations” companies have a potential upside of 31.83%. Given Eledon Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts plainly believe Eledon Pharmaceuticals is more favorable than its competitors.

Summary

Eledon Pharmaceuticals beats its competitors on 7 of the 13 factors compared.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. The company's lead product is OP0201, a surfactant-based nasal aerosol drug-device combination product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection). It also has a foam-based drug delivery technology OP0101 and OP0102 that could be used to deliver drugs into the ear, nose, and sinus cavities. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.